Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores
Company leadership is framing the move as transformational.
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Its a major breakthrough for women’s ovarian cancer care in Europe
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Subscribe To Our Newsletter & Stay Updated
